Medications Development of Stimulant Dependence

承包商应在任务订单的基础上，根据国家药物滥用研究所（NIDA）、治疗研究与开发部（DTR&D）“兴奋剂依赖药物开发（MDS）”项目进行I、II或III期临床试验。这些网站将评估药物治疗化合物在治疗药物滥用方面的临床效用。具体地说，将研究减少兴奋剂（即可卡因和甲基苯丙胺）使用和防止复发的药物治疗化合物。这些临床试验的结果可以提交给FDA，以支持新药申请（NDA）的提交。该合同的主要重点将放在临床试验上，以评估候选化合物的临床药理学、疗效和安全性。

The Contractor shall, on a task order basis, conduct Phase I, II, or III clinical trials under the National Institute on Drug Abuse (NIDA), Division of Treatment Research and Development (DTR&D) program for ¿Medications Development of Stimulant Dependence (MDS)'. These sites will evaluate the clinical utility of pharmacotherapeutic compounds for the treatment of drug abuse. Specifically, pharmacotherapeutic compounds to reduce the use of stimulants (i.e., cocaine and methamphetamine) and prevent relapse will be investigated. The results of these clinical trials may be submitted to the FDA in support of New Drug Application (NDA) submissions. The major emphasis of this contract will be on clinical trials to evaluate the clinical pharmacology, efficacy and safety profiles of the candidate compounds.